Oducing panNET. The main internet site from the NET was the pancreas in 14 patients (64 ), the lung in five (23 ), as well as the gastro-intestinal tract in 2 (9 ), while in 1 patient, there was a double main (pancreas and small bowel). Among the 5 individuals with lungCurr. Oncol. 2023,NETs, four of them had an atypical carcinoid, and one particular a typical carcinoid. In line with WHO’s 2019 classification, three individuals (14 ) had a grade-1 tumor, twelve (54 ) a grade two, and seven (32 ) a grade three. The median Ki-67 was 15 (IQR 85). The MGMT promoter was methylated in five tumors (23 ), all of which were panNETs, accounting for any 33 (5/15) relative frequency of MGMT-methylated tumors within this group. The baseline patients’ characteristics by the MGMT-methylation status are reported in Table 2.Table 1. Patients’ characteristics. Characteristic All round Gender (female) Age (years), median (IQR) ECOG PS 0 MEN-1 syndrome Functioning NET Main tumor website Pancreas: Head Body Tail Lung: Atypical carcinoid Standard carcinoid Gastro-intestinal: Stomach Ileum Double site (pancreas and ileum) WHO’s 2019 grading: G1 G2 G3 Ki-67 ( ), median (IQR) MGMT-promoter methylation n ( ) 22 (one hundred ) 13 (59 ) 64 (564) 18 (82 ) 1 (five ) 1 (5 ) 14 (64 ) 7 four 3 5 (23 ) 4 1 2 (9 ) 1 1 1 (5 ) 3 (14 ) 12 (54 ) 7 (32 ) 15 [85] five (23 )IQR–interquartile variety; ECOG PS–Eastern Cooperative Oncology Group overall performance status; WHO–World Wellness Organization; G–grade; MGMT–O6-methyl-guanine-DNA methyl-transferase.Table 2. Patients’ baseline qualities by MGMT-promoter methylation status. Characteristic Overall Gender (female) Age (years), median (IQR) ECOG PS 0 MEN-1 syndrome Functioning NET Primary tumor web site Pancreas: Head Body Tail Lung: Atypical carcinoid Typical carcinoid Gastro-intestinal: Stomach Ileum Unmethylated MGMT 17 11 66 (563) 14 1 1 9 4 3 two five four 1 two 1 1 Methylated MGMT 5 2 74 (607) 4 0 0 five 3 1 1Curr.Arginase-1/ARG1 Protein Biological Activity Oncol.CD162/PSGL-1 Protein Source 2023,Table 2. Cont. Characteristic Double web site (pancreas and ileum) WHO’s 2019 grading: G1 G2 G3 Ki-67 ( ), median (IQR) Therapy regimen: TEM CAPTEM Unmethylated MGMT 1 three 10 4 15 (72) 9 8 Methylated MGMT 0 0 two 3 25 (61) 2IQR–interquartile variety; ECOG PS–Eastern Cooperative Oncology Group efficiency status; WHO–World Wellness Organization; G–grade; MGMT–O6-methyl-guanine-DNA methyl-transferase; TEM–temozolomide; CAPTEM–capecitabine and temozolomide doublet.PMID:24120168 3.2. TEM-Based Therapy Eleven sufferers (50 ) received CAPTEM and eleven patients (50 ) received TEM as monotherapy (Table 3). On the 11 individuals undergoing CAPTEM remedy, 2 discontinued capecitabine but continued the TEM remedy: 1 patient for toxicity and 1 as maintenance therapy immediately after 42 cycles of CAPTEM combination. TEM-based was the first-line remedy in eight circumstances (36 ), the second line in five (23 ), along with the third or beyond line in nine (41 ). The median time to progression observed within the previous therapy line was 7.5 months (95 CI 45). The median duration of the TEM-based remedy was 13 months (95 CI 94), using a median number of cycles of 12 (IQR 92). The median follow-up time was 23 (IQR 134) months. At the time from the information analysis (October 15, 2022), 11 sufferers (50 ) have been nonetheless receiving TEM-based therapy, 2 (9 ) discontinued remedy following a long-lasting response, three (14 ) discontinued treatment for AEs, and six (27 ) discontinued for PD, of whom four had died. In our cohort, three (60 ) out on the five MGMT-methylated individuals received the doublet therapy (CAPTEM), though two (40 ) receiv.
